Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Ryplazim - maybe revenue 2021?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(23)
•••
Comment by Thesweethearton Oct 18, 2019 12:51pm
60 Views
Post# 30244386

RE:Ryplazim - maybe revenue 2021?

RE:Ryplazim - maybe revenue 2021?
stockbuphoon wrote:

If they can get approval by mid- 2020, did any of the 500 people at PLI or Liminal get any insurance companies on board to actually get paid for Ryplazim? Total market for CPD is maybe $200M but more likely a slow ramp up. 

Regards
Paul



maybe a few hun mil more? Rypl has nothing to do with lmnl!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities